GlassScriptPhysician profile
Julia Y Oweis
NPI 1487699260
$2,562.06
in general payments reported to CMS, 2019-2025
27 companies · $1,006 in 2025
The $1,006 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $113 · 2021: $122 · 2023: $355 · 2024: $668 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,028.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $518.63 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $377.93 | 2019-2025 | Airsupra |
| Novo Nordisk INC | $336.04 | 2024-2025 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $222.38 | 2019-2020 | |
| Shield Therapeutics INC | $152.67 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $147.53 | 2023 | Quviviq |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2023 | Dupixent |
| Viiv Healthcare Company | $102.50 | 2025 | Apretude |
| Lilly USA, LLC | $72.12 | 2024-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $64.41 | 2025 | The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.20 | 2021 | |
| Phadia US INC. | $39.80 | 2019-2024 | Immunocap |
| Abbvie INC. | $33.10 | 2025 | |
| Horizon Therapeutics Plc | $32.17 | 2019 | |
| Pfizer INC. | $29.85 | 2021-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.45 | 2025 | Ofev |
| Teva Pharmaceuticals USA, INC. | $26.00 | 2019 | |
| Tempus Ai, INC | $25.76 | 2025 | Xt Cdx |
| Sanofi-Aventis U.S. LLC | $24.76 | 2021 | |
| Amgen INC. | $22.16 | 2025 | Otezla |
| Xeris Pharmaceuticals, INC. | $22.15 | 2025 | Recorlev |
| Rgh Enterprises LLC | $20.07 | 2025 | |
| Inspire Medical Systems, INC. | $19.66 | 2025 | Inspire |
| Nabriva Therapeutics, Plc | $18.38 | 2020 | |
| Esperion Therapeutics, INC. | $17.91 | 2021 | |
| Alk-Abello, INC | $17.78 | 2023 | Grastek, Ragwitek, Odactra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Oweis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.